(CNTA) Centessa Pharmaceuticals - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 6.150m USD | Total Return: 198.3% in 12m
Avg Turnover: 37.6M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Share dilution 15.4% YoY
Interest Coverage Ratio -23.5 is critical
Altman Z'' -2.98 < 1.0 - financial distress zone
Tailwinds
Rs Leader, Idiosyncratic Leader, Tailwind
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company focused on the discovery and development of orexin-based neuroscience therapeutics. Its lead candidate, ORX750, is currently in Phase IIa clinical trials targeting central disorders of hypersomnolence, such as narcolepsy and idiopathic hypersomnia. The company’s pipeline also includes Phase I programs for neurological and neuropsychiatric disorders, alongside an early-stage immuno-oncology platform known as LockBody.
Operating within the biotechnology sector, Centessa utilizes a hub-and-spoke business model designed to accelerate drug development by centralizing administrative resources while allowing individual programs to operate with specialized scientific autonomy. The development of orexin receptor agonists represents a high-growth area in sleep medicine, as these therapies aim to address the underlying deficiency of orexin peptides in the brain. For a more detailed breakdown of the companys valuation and pipeline potential, consult the tools available on ValueRay.
- ORX750 Phase 2a clinical trial results drive near-term equity valuation
- Expansion of orexin agonist pipeline impacts long-term research and development costs
- Competitive landscape for narcolepsy treatments influences projected market share capture
- Future capital requirements depend on clinical progression of early-stage LockBody platform
- Regulatory approval milestones for hypersomnolence therapies dictate path to commercial revenue
| Net Income: -250.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.34 > 0.02 and ΔFCF/TA 1.20 > 1.0 |
| NWC/Revenue: 2.08k% < 20% (prev 2.03k%; Δ 52.67% < -1%) |
| CFO/TA -0.33 > 3% & CFO -208.8m > Net Income -250.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 9.53 > 1.5 & < 3 |
| Outstanding Shares: last quarter (153.5m) vs 12m ago 15.42% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 2.56% > 50% (prev 3.02%; Δ -0.46% > 0%) |
| Interest Coverage Ratio: -23.51 > 6 (EBIT TTM -265.8m / Interest Expense TTM 11.3m) |
| A: 0.49 (Total Current Assets 348.7m - Total Current Liabilities 36.6m) / Total Assets 641.8m |
| B: -1.97 (Retained Earnings -1.27b / Total Assets 641.8m) |
| C: -0.45 (EBIT TTM -265.8m / Avg Total Assets 584.8m) |
| D: 3.16 (Book Value of Equity 487.3m / Total Liabilities 154.4m) |
| Altman-Z'' = -2.98 = D |
As of June 04, 2026, the stock is trading at USD 39.85 with a total of 839,603 shares traded.
Over the past week, the price has changed by +0.20%,
over one month by +0.38%,
over three months by +52.10% and
over the past year by +198.28%.
Centessa Pharmaceuticals has received a consensus analysts rating of 4.64. Therefore, it is recommended to buy CNTA.
- StrongBuy: 7
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 44.6 | 11.8% |
P/S = 409.2065
P/B = 12.6203
Revenue TTM = 15.0m USD
EBIT TTM = -265.8m USD
EBITDA TTM = -265.8m USD
Long Term Debt = 110.4m USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 118.6m USD (corrected: LT Debt 110.4m + ST Debt none) + Leases 8.12m
Net Debt = -158.0m USD (calculated: Debt 118.6m - CCE 276.6m)
Enterprise Value = 5.99b USD (6.15b + Debt 118.6m - CCE 276.6m)
Interest Coverage Ratio = -23.51 (Ebit TTM -265.8m / Interest Expense TTM 11.3m)
EV/FCF = -27.69x (Enterprise Value 5.99b / FCF TTM -216.4m)
FCF Yield = -3.61% (FCF TTM -216.4m / Enterprise Value 5.99b)
FCF Margin = -1.44k% (FCF TTM -216.4m / Revenue TTM 15.0m)
Net Margin = -1.67k% (Net Income TTM -250.6m / Revenue TTM 15.0m)
Gross Margin = unknown ((Revenue TTM 15.0m - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 9.34 (Enterprise Value 5.99b / Total Assets 641.8m)
Interest Expense / Debt = 9.54% (Interest Expense 11.3m / Debt 118.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -210.0m (EBIT -265.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.38 (Total Current Assets 348.7m / Total Current Liabilities 47.2m)
Debt / Equity = 0.24 (Debt 118.6m / totalStockholderEquity, last quarter 487.3m)
Debt / EBITDA = 0.59 (negative EBITDA) (Net Debt -158.0m / EBITDA -265.8m)
Debt / FCF = 0.73 (negative FCF - burning cash) (Net Debt -158.0m / FCF TTM -216.4m)
Total Stockholder Equity = 415.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -42.86% (Net Income -250.6m / Total Assets 641.8m)
RoE = -60.37% (Net Income TTM -250.6m / Total Stockholder Equity 415.2m)
RoCE = -50.58% (EBIT -265.8m / Capital Employed (Equity 415.2m + L.T.Debt 110.4m))
RoIC = -34.75% (negative operating profit) (NOPAT -210.0m / Invested Capital 604.4m)
WACC = 7.80% (E(6.15b)/V(6.27b) * Re(7.81%) + D(118.6m)/V(6.27b) * Rd(9.54%) * (1-Tc(0.21)))
Discount Rate = 7.81% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 22.13%
[DCF] Fair Price = unknown (Cash Flow -216.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.81 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.40 | Chg30d=+23.91% | Revisions=+14% | Analysts=6
EPS next Quarter (2026-09-30): EPS=-0.42 | Chg30d=+24.24% | Revisions=+14% | Analysts=6
EPS current Year (2026-12-31): EPS=-1.56 | Chg30d=+11.43% | Revisions=-14% | GrowthEPS=-6.9% | GrowthRev=-100.0%
EPS next Year (2027-12-31): EPS=-1.90 | Chg30d=-0.06% | Revisions=-25% | GrowthEPS=-21.6% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -25%